425 related articles for article (PubMed ID: 29521242)
1. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Novel Therapy for Multidrug Resistant Gram Negative Infections in Children.
Rodriguez BA; Girotto JE; Nicolau DP
Curr Pediatr Rev; 2018; 14(2):97-109. PubMed ID: 29521242
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Liscio JL; Mahoney MV; Hirsch EB
Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591
[TBL] [Abstract][Full Text] [Related]
3. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
4. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
Gentile I; Maraolo AE; Borgia G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
[No Abstract] [Full Text] [Related]
5. Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.
Grupper M; Sutherland C; Nicolau DP
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739780
[TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
7. [Clinical aspects of severe infections caused by antibiotic-resistant Gram-negative bacteria. The Empire strikes back?].
Sinkó J
Orv Hetil; 2017 Oct; 158(39):1528-1534. PubMed ID: 28942664
[TBL] [Abstract][Full Text] [Related]
8. The β-Lactams Strike Back: Ceftazidime-Avibactam.
Zasowski EJ; Rybak JM; Rybak MJ
Pharmacotherapy; 2015 Aug; 35(8):755-70. PubMed ID: 26289307
[TBL] [Abstract][Full Text] [Related]
9. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
[TBL] [Abstract][Full Text] [Related]
10. Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.
Shirley M
Drugs; 2018 Apr; 78(6):675-692. PubMed ID: 29671219
[TBL] [Abstract][Full Text] [Related]
11. Management of multidrug-resistant Pseudomonas aeruginosa in the intensive care unit: state of the art.
Maraolo AE; Cascella M; Corcione S; Cuomo A; Nappa S; Borgia G; De Rosa FG; Gentile I
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):861-871. PubMed ID: 28803496
[TBL] [Abstract][Full Text] [Related]
12. Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against Pseudomonas aeruginosa: PRIMERS IV.
Evans SR; Tran TTT; Hujer AM; Hill CB; Hujer KM; Mediavilla JR; Manca C; Domitrovic TN; Perez F; Farmer M; Pitzer KM; Wilson BM; Kreiswirth BN; Patel R; Jacobs MR; Chen L; Fowler VG; Chambers HF; Bonomo RA;
Clin Infect Dis; 2019 May; 68(11):1823-1830. PubMed ID: 30239599
[TBL] [Abstract][Full Text] [Related]
13. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations.
van Duin D; Bonomo RA
Clin Infect Dis; 2016 Jul; 63(2):234-41. PubMed ID: 27098166
[TBL] [Abstract][Full Text] [Related]
14. The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Clerici D; Oltolini C; Greco R; Ripa M; Giglio F; Mastaglio S; Lorentino F; Pavesi F; Farina F; Liberatore C; Castiglion B; Tassan Din C; Bernardi M; Corti C; Peccatori J; Scarpellini P; Ciceri F; Castagna A
Int J Antimicrob Agents; 2021 Jun; 57(6):106335. PubMed ID: 33838223
[TBL] [Abstract][Full Text] [Related]
15. Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
Falcone M; Paterson D
J Antimicrob Chemother; 2016 Oct; 71(10):2713-22. PubMed ID: 27432599
[TBL] [Abstract][Full Text] [Related]
16. Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis.
Gatti M; Raschi E; De Ponti F
Eur J Clin Microbiol Infect Dis; 2021 Jun; 40(6):1169-1176. PubMed ID: 33415492
[TBL] [Abstract][Full Text] [Related]
17. New and Emerging Antibiotics for Complicated Intra-Abdominal Infections.
Durand CR; Alsharhan M; Willett KC
Am J Ther; 2017; 24(6):e763-e769. PubMed ID: 26796653
[TBL] [Abstract][Full Text] [Related]
18. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
[TBL] [Abstract][Full Text] [Related]
19. Ceftolozane/tazobactam and ceftazidime/avibactam antimicrobial activity against clinically relevant gram-negative bacilli isolated in Mexico.
Martínez-Miranda R; Gastélum-Acosta M; Guerrero-Estrada P; Ayala-Figueroa RI; Osuna-Álvarez LE
Gac Med Mex; 2020; 156(6):592-597. PubMed ID: 33877120
[TBL] [Abstract][Full Text] [Related]
20. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
